Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
The School of Medicine, University of St. Andrews, St. Andrews, United Kingdom.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00652-19. Print 2019 Oct.
The molecular bacterial load (MBL) assay is a new tuberculosis biomarker which provides results in ∼4 hours. The relationship between MBL and time-to-positivity (TTP) has not been thoroughly studied, and predictive models do not exist. We aimed to develop a model for MBL and identify the MBL-TTP relationship in patients. The model was developed on data from 105 tuberculosis patients from Malawi, Mozambique, and Tanzania with joint MBL and TTP observations quantified from patient sputum collected for 12 weeks. MBL was quantified using PCR of mycobacterial RNA and TTP using the mycobacterial growth indicator tube (MGIT) 960 system. Treatment consisted of isoniazid, pyrazinamide, and ethambutol in standard doses together with rifampin 10 or 35 mg/kg of body weight. The developed MBL-TTP model included several linked submodels, a component describing decline of bacterial load in sputum, another component describing growth in liquid culture, and a hazard model translating bacterial growth into a TTP signal. Additional components for contaminated and negative TTP samples were included. Visual predictive checks performed using the developed model gave good description of the observed data. The model predicted greater total sample loss for TTP than MBL due to contamination and negative samples. The model detected an increase in bacterial killing for 35 versus 10 mg/kg rifampin ( = 0.002). In conclusion, a combined model for MBL and TTP was developed that described the MBL-TTP relationship. The full MBL-TTP model or each submodel was used separately. Second, the model can be used to predict biomarker response for MBL given TTP data or in historical or future trials.
细菌载量(MBL)检测是一种新的结核病生物标志物,可在大约 4 小时内得出结果。MBL 与阳性时间(TTP)之间的关系尚未得到深入研究,也没有预测模型。我们旨在为 MBL 建立一个模型,并确定患者中 MBL-TTP 的关系。该模型是在马拉维、莫桑比克和坦桑尼亚的 105 名结核病患者的数据上建立的,这些患者的 MBL 和 TTP 观察值是从收集的 12 周患者痰液中联合定量的。MBL 是通过聚合酶链反应(PCR)检测结核分枝杆菌 RNA 进行量化的,TTP 是通过分枝杆菌生长指示管(MGIT)960 系统进行量化的。治疗方案包括标准剂量的异烟肼、吡嗪酰胺和乙胺丁醇,以及利福平 10 或 35mg/kg 体重。所开发的 MBL-TTP 模型包括几个链接的子模型,一个描述痰液中细菌负荷下降的组件,另一个描述液体培养中生长的组件,以及一个将细菌生长转化为 TTP 信号的危险模型。还包括了对污染和阴性 TTP 样本的附加组件。使用所开发的模型进行的可视化预测检查很好地描述了观察到的数据。该模型预测 TTP 样本的总损失大于 MBL 样本,这是由于污染和阴性样本造成的。该模型检测到 35 毫克/千克利福平与 10 毫克/千克利福平相比,细菌杀伤作用增加(=0.002)。总之,建立了一个 MBL 和 TTP 的联合模型,描述了 MBL-TTP 的关系。该模型或每个子模型都可单独使用。其次,该模型可用于根据 TTP 数据预测 MBL 生物标志物的反应,或者在历史或未来的试验中预测。